Relmada Therapeutics, Inc.
RLMDNASDAQHealthcare● Active
$5.72
$-0.23(-3.87%)
Market Cap$419468318
P/E Ratio—
52W High$8
52W Low$0.52
Relmada Therapeutics, Inc. (RLMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RLMD · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.22
Est. -$0.18 · -22.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
RLMD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.19 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.18 | -$0.22 | -22.2% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.14 | -$0.27 | -92.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.04 | -$0.30 | -650.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.25 | -$0.30 | -20.0% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.31 | -$0.58 | -87.1% | — | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.70 | -$0.62 | +11.4% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.65 | -$0.72 | -10.8% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.22
EPS Est.
-$0.18
EPS Surpr.
-22.2%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.14
EPS Surpr.
-92.9%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.04
EPS Surpr.
-650.0%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.25
EPS Surpr.
-20.0%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.58
EPS Est.
-$0.31
EPS Surpr.
-87.1%
Revenue
—
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$0.70
EPS Surpr.
+11.4%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.72
EPS Est.
-$0.65
EPS Surpr.
-10.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q2 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q1 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.19 | $-0.19 | $-0.19 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -22.2% | $7.36 | $7.45 | +1.22% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -92.9% | $6.21 | $6.25 | +0.64% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -650.0% | $3.91 | $3.88 | -0.77% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -20.0% | $0.60 | $0.60 | +0.48% |
| ▼ Q2 FY2025 | May 12, 2025 | -87.1% | $0.42 | $0.40 | -5.05% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +11.4% | $0.31 | $0.30 | -2.90% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -10.8% | $0.85 | $0.82 | -4.12% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +28.9% | $0.81 | $0.81 | +0.00% |
Q2 FY2026+1.22%
Report Date
May 12, 2026
EPS Beat/Miss
-22.2%
Price Before
$7.36
Price After
$7.45
Q1 FY2026+0.64%
Report Date
Mar 19, 2026
EPS Beat/Miss
-92.9%
Price Before
$6.21
Price After
$6.25
Q4 FY2025-0.77%
Report Date
Nov 13, 2025
EPS Beat/Miss
-650.0%
Price Before
$3.91
Price After
$3.88
Q3 FY2025+0.48%
Report Date
Aug 7, 2025
EPS Beat/Miss
-20.0%
Price Before
$0.60
Price After
$0.60
Q2 FY2025-5.05%
Report Date
May 12, 2025
EPS Beat/Miss
-87.1%
Price Before
$0.42
Price After
$0.40
Q1 FY2025-2.90%
Report Date
Mar 27, 2025
EPS Beat/Miss
+11.4%
Price Before
$0.31
Price After
$0.30
Q4 FY2024-4.12%
Report Date
Nov 7, 2024
EPS Beat/Miss
-10.8%
Price Before
$0.85
Price After
$0.82
Q3 FY2024+0.00%
Report Date
Aug 7, 2024
EPS Beat/Miss
+28.9%
Price Before
$0.81
Price After
$0.81
Avg Beat Reaction-1.45%
Avg Miss Reaction-1.27%
Beat Rate2 / 8 quarters
Largest Move-5.05% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RLMD ends December
Relmada Therapeutics, Inc. (RLMD) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.22 — missing the analyst consensus of $-0.18 by -22.2%. The next RLMD earnings date is expected around September 1, 2026.
Each quarter, investors track RLMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RLMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RLMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RLMD earnings · 5 questionsRelmada Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. RLMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RLMD historically reports after market close (AMC).
RLMD earnings datewhen is RLMD earningsRLMD next earnings datewhen does RLMD report earningsRLMD earnings calendar
▸ Source: FMP · Relmada Therapeutics, Inc. SEC filings · US GAAP · Relmada Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026